Raises FY23 revenue view to $126M-$129M from $124M-$126M, consensus $126.5M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LGND:
- Sermonix announces case report during ELAINE-1 study of Lasofoxifene
- Ligand Pharmaceuticals Inc (LGND) Q3 Earnings Cheat Sheet
- Ligand acquires Tolerance Therapeutics for $20M in cash
- Biotech Alert: Searches spiking for these stocks today
- Ovid Therapeutics, Ligand enter $30M agreement for soticlestat
